Berit Kriström1, Elena Lundberg, Björn Jonsson, Kerstin Albertsson-Wikland. 1. Department of Clinical Science (B.K., E.L.), Pediatrics, Umeå University, SE-90185 Umeå, Sweden; Department of Women's and Children's Health (B.J.), Uppsala University, SE-75185 Uppsala, Sweden; and Göteborg Pediatric Growth Research Center (B.K., K.A.-W.), Department of Pediatrics, Institute of Clinical Sciences, The Sahlgrenska Academy at University of Gothenburg, SE-41685 Gothenburg, Sweden.
Abstract
CONTEXT: GH treatment significantly increased adult height (AH) in a dose-dependent manner in short non-GH-deficient children in a randomized, controlled, clinical trial; the mean gain in height SD score (heightSDS) was 1.3 (range 0-3), compared with 0.2 in the untreated group. OBJECTIVE: The objective of the study was to analyze the relationship between IGF-1SDS, IGF binding protein-3 SDS (IGFBP3SDS), and their ratioSDS with a gain in the heightSDS until AH in non-GH-deficient short children. DESIGN AND SETTING: This was a randomized, controlled, multicenter clinical trial. INTERVENTION: The intervention included GH treatment: 33 or 67 μg/kg · d plus untreated controls. SUBJECTS:One hundred fifty-one non-GH-deficient short children were included in the intent-to-treat (ITT) population and 108 in the per-protocol (PP) population; 112 children in the ITT and 68 children in the PP populations had idiopathic short stature (ISS). MAIN OUTCOME MEASURES: Increments from baseline to on-treatment study mean IGF-1SDS (ΔIGF-1SDS), IGFBP3SDS, and IGF-1 to IGFBP3 ratioSDS were assessed in relationship to the gain in heightSDS. RESULTS: Sixty-two percent of the variance in the gain in heightSDS in children on GH treatment could be explained by four variables: ΔIGF-1SDS (explaining 28%), bone age delay, birth length (the taller the better), and GH dose (the higher the better). The lower IGF-1SDS was at baseline, the higher was its increment during treatment. For both the AllPP- and the ISSPP-treated groups, the attained IGF-1SDS study level did not correlate with height gain. CONCLUSION: In short non-GH-deficient children, the GH dose-related increment in IGF-1SDS from baseline to mean study level was the most important explanatory variable for long-term growth response from the peripubertal period until AH, when IGF-1SDS, IGFBP3SDS, and their ratioSDS were compared concurrently.
RCT Entities:
CONTEXT: GH treatment significantly increased adult height (AH) in a dose-dependent manner in short non-GH-deficient children in a randomized, controlled, clinical trial; the mean gain in height SD score (heightSDS) was 1.3 (range 0-3), compared with 0.2 in the untreated group. OBJECTIVE: The objective of the study was to analyze the relationship between IGF-1SDS, IGF binding protein-3 SDS (IGFBP3SDS), and their ratioSDS with a gain in the heightSDS until AH in non-GH-deficient short children. DESIGN AND SETTING: This was a randomized, controlled, multicenter clinical trial. INTERVENTION: The intervention included GH treatment: 33 or 67 μg/kg · d plus untreated controls. SUBJECTS: One hundred fifty-one non-GH-deficient short children were included in the intent-to-treat (ITT) population and 108 in the per-protocol (PP) population; 112 children in the ITT and 68 children in the PP populations had idiopathic short stature (ISS). MAIN OUTCOME MEASURES: Increments from baseline to on-treatment study mean IGF-1SDS (ΔIGF-1SDS), IGFBP3SDS, and IGF-1 to IGFBP3 ratioSDS were assessed in relationship to the gain in heightSDS. RESULTS: Sixty-two percent of the variance in the gain in heightSDS in children on GH treatment could be explained by four variables: ΔIGF-1SDS (explaining 28%), bone age delay, birth length (the taller the better), and GH dose (the higher the better). The lower IGF-1SDS was at baseline, the higher was its increment during treatment. For both the AllPP- and the ISSPP-treated groups, the attained IGF-1SDS study level did not correlate with height gain. CONCLUSION: In short non-GH-deficient children, the GH dose-related increment in IGF-1SDS from baseline to mean study level was the most important explanatory variable for long-term growth response from the peripubertal period until AH, when IGF-1SDS, IGFBP3SDS, and their ratioSDS were compared concurrently.
Authors: Barry Bogin; Michael Hermanussen; Werner F Blum; Christian Aßmann Journal: Int J Environ Res Public Health Date: 2015-05-04 Impact factor: 3.390
Authors: Min Jae Kang; Eun Young Kim; Young Suk Shim; Hwal Rim Jeong; Hye Jin Lee; Seung Yang; Il Tae Hwang Journal: Medicine (Baltimore) Date: 2019-04 Impact factor: 1.817
Authors: Gudmundur Johannsson; Martin Bidlingmaier; Beverly M K Biller; Margaret Boguszewski; Felipe F Casanueva; Philippe Chanson; Peter E Clayton; Catherine S Choong; David Clemmons; Mehul Dattani; Jan Frystyk; Ken Ho; Andrew R Hoffman; Reiko Horikawa; Anders Juul; John J Kopchick; Xiaoping Luo; Sebastian Neggers; Irene Netchine; Daniel S Olsson; Sally Radovick; Ron Rosenfeld; Richard J Ross; Katharina Schilbach; Paulo Solberg; Christian Strasburger; Peter Trainer; Kevin C J Yuen; Kerstin Wickstrom; Jens O L Jorgensen Journal: Endocr Connect Date: 2018-02-26 Impact factor: 3.335